Skip to main content
. 2022 Jun 14;29(12):1854–1865. doi: 10.1038/s41417-022-00484-z

Fig. 1. ODN2395 administered via PV is more effective in inhibiting tumor progression.

Fig. 1

A. Schema: Schematic representation of the timeline of LM generation and the treatment protocol. Eight- to twelve-week-old C57/BL6 mice were challenged using intra-splenic injection model with 2.5 × 106 MC38-CEA-Luc cells for 7 days (D-7). Bioluminescence value was determined by IVIS on D0, D1, D2, and mice were randomized accordingly and treated with 1, 3, 10, or 30 µg/mouse ODN2395 via portal vein (PV) and 30 µg/mouse ODN2395 via tail vein (TV). PBS served as the vehicle (Veh) control and administered via PV. On D2 post-treatment with ODN2395 or Veh, mice were sacrificed, and liver was harvested to isolate CD45+ cells. Isolated CD45+ NPCs were evaluated for MDSCs and macrophages (M1 and M2). B Tumor progression was monitored by IVIS imaging on the day of treatment (D0), D1, and D2 post-treatment. Fold change of the tumor burden was calculated based on D0 baseline bioluminescence. Multiple t test was performed to determine the significant difference. C Harvested LM tissues (whole lysates) from n = 6 mice/group (representative of n = 3 shown) were evaluated for pNFκB (p65S536), pSTAT3Y705, total NFκB, STAT3, and IL6 by western blotting. GAPDH was used as a housekeeping protein control.